Controlled release metformin compositions
US6866866B1 · kind B1 · utility
19Cited by
10References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 3, 2000 |
| Grant date | Mar 15, 2005 |
| Priority date | — |
| Expiry date | Apr 14, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2027
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.